Pluvicto Moves to First-Line Therapy: Estimating the Corridor's New Eligible Population

On July 31, the FDA approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan) in combination with an androgen receptor pathway inhibitor for PSMA-positive metastatic hormone-sensitive prostate cancer, now termed metastatic androgen pathway modulation-naive or -sensitive disease in the label. Pluvicto no longer requires progression on hormone therapy before it can be used. It is now given alongside the ADT and ARPI a newly diagnosed metastatic patient already receives.

Since its first approval in 2022, Pluvicto had been restricted to patients whose cancer had already progressed on hormone therapy, and in most cases after chemotherapy as well. This approval moves the drug to first-line use. Novartis reports that this change nearly doubles the number of men nationally who meet eligibility criteria.

What that shift means for the corridor ARC serves is worth working out directly rather than taking the national figure at face value. The following estimate does that.

What Changed Clinically

The approval rests on PSMAddition, a Phase 3 trial of 1,144 men with PSMA-positive metastatic hormone-sensitive prostate cancer randomized within 45 days of ADT initiation. Adding Pluvicto to ADT plus an ARPI reduced the risk of progression or death by 33% relative to ADT and ARPI alone, with a positive trend in overall survival.

About a third of men on ADT plus ARPI never reach an undetectable PSA, and roughly half progress to castration-resistant disease within 20 months. The requirement to wait for that progression before offering Pluvicto reflected the label rather than the underlying biology. PSMAddition tested whether earlier initiation improves outcomes, and the trial demonstrated that it does.

The PSMA biomarker is present in more than 80% of prostate cancer patients, which extends this approval's relevance to most newly diagnosed metastatic cases rather than a narrow subset.

Sizing the Corridor's New Population

Prostate cancer incidence data were obtained from State Cancer Profiles, the SEER-based tool maintained jointly by NCI and CDC, for the Appalachian Regional Commission counties across the three corridor states: 52 counties in East Tennessee, 25 in Southwest Virginia, and 31 in Western North Carolina.

Applying the national distant-stage-at-diagnosis rate of 8% (CDC, 2017–2021) to the corridor total yields approximately 305 men per year diagnosed with prostate cancer that is already metastatic at the point hormone therapy begins. Applying the PSMA-positivity rate established in the trial population to that figure yields approximately 240 to 250 men per year in this corridor who are now Pluvicto-eligible at diagnosis rather than only after progression through hormone therapy.

This is a modeled estimate rather than a registry count, and the method is stated explicitly here rather than presented as more precise than the underlying data support.

Each input in this chain is a cited, verifiable figure. The combination remains a model rather than a measurement, and a precise count would require corridor-specific stage-at-diagnosis data that is not publicly available at the county level.

What This Estimate Does Not Capture

The estimate of 240 to 250 patients per year represents the corridor's new front-line population: the men who will now be considered for Pluvicto at diagnosis rather than after progression. It does not include the corridor's existing castration-resistant population, patients originally diagnosed at an earlier stage who progressed to metastatic, hormone-resistant disease over the following months or years. This is a prevalence figure that accumulates over time rather than a quantity a single year of incidence data can capture, and it represents the population Pluvicto has treated in this corridor since its 2022 approval.

Implications for Referral Timing

The practical shift concerns not only which patients qualify but when the referral conversation occurs. Under the prior label, a referring oncologist or urologist could reasonably defer consideration of PSMA-targeted therapy until PSA began rising on ADT. Under the current label, that conversation, along with the PSMA PET scan required before it, needs to occur at diagnosis.

In a corridor where theranostics capacity is concentrated in a small number of institutions, this represents a meaningful shift in referral timing and, ultimately, in the volume of PSMA PET scans and treatment planning cycles those programs need to support annually.